Ultrasound Fibroscan Test in Pakistan at Chughtai Lab

Ultrasound Fibroscan at Chughtai Lab

An Ultrasound Fibroscan, medically known as transient elastography, is a highly specialized, non-invasive diagnostic imaging modality used to assess liver health. This cutting-edge technology measures liver stiffness (elasticity) and hepatic steatosis (fat accumulation) without the need for an invasive liver biopsy. At Chughtai Lab, one of Pakistan’s premier diagnostic networks, this advanced procedure is performed using state-of-the-art Fibroscan equipment, providing clinicians with precise, quantitative data to evaluate chronic liver diseases. The test works by emitting a low-frequency shear wave (50 Hz) through the liver tissue via an ultrasound transducer. The velocity of this wave is directly proportional to the stiffness of the liver: faster waves indicate stiffer, more fibrotic tissue, while slower waves indicate healthy, compliant hepatic tissue.

The primary anatomical structure evaluated during an Ultrasound Fibroscan is the right lobe of the liver. The probe is positioned in the intercostal spaces, allowing the shear waves to pass through the hepatic parenchyma. This diagnostic tool holds immense clinical importance because liver fibrosis—the progressive scarring of liver tissue resulting from chronic inflammation—is often asymptomatic in its early stages. By detecting fibrosis early, hepatologists, gastroenterologists, and internal medicine specialists can initiate timely therapeutic interventions, monitor disease progression, and evaluate the efficacy of ongoing treatments. The diagnostic value of a Fibroscan lies in its ability to provide immediate, reproducible, and highly accurate results, making it an indispensable tool in modern hepatology.

The benefits of undergoing an Ultrasound Fibroscan at Chughtai Lab are substantial. Unlike a traditional liver biopsy, which carries risks of pain, bleeding, and hospitalization, a Fibroscan is entirely painless, non-invasive, and requires no post-procedure recovery time. It samples a volume of liver tissue that is approximately 100 times larger than a typical biopsy core, reducing sampling error and providing a more representative assessment of the entire organ. Common clinical indications for this test include chronic hepatitis B and C infections, metabolic dysfunction-associated steatotic liver disease (MASLD, formerly known as NAFLD), alcoholic liver disease, autoimmune hepatitis, and unexplained elevations in liver enzymes.

Clinical Procedure: What to Expect

Patient Preparation

To ensure the highest level of accuracy and prevent false elevations in liver stiffness measurements, patients must adhere to specific preparation guidelines before undergoing an Ultrasound Fibroscan at Chughtai Lab:

• Fasting Requirements: Patients must fast (no food or liquids, including water) for a minimum of 3 to 4 hours prior to the procedure. Consuming food increases blood flow to the liver (postprandial hyperemia), which temporarily increases liver stiffness and can lead to an overestimation of fibrosis.
• Medication Guidelines: Routine medications may be taken with a small sip of water, unless otherwise instructed by the referring physician.
• Clothing: Patients should wear loose, comfortable clothing that allows easy access to the right side of the chest and upper abdomen.
• Medical History: Patients should bring all previous liver function tests, abdominal ultrasound reports, and relevant medical records to the appointment.
• Contraindications: It is essential to inform the technician if you are pregnant, have an active implantable medical device (such as a pacemaker or defibrillator), or have severe ascites (fluid accumulation in the abdomen), as these conditions may affect the feasibility or safety of the test.

During the Procedure

The Ultrasound Fibroscan procedure is straightforward, comfortable, and typically completed within 10 to 15 minutes. Upon entering the examination room at Chughtai Lab, the patient is asked to lie flat on their back (supine position) on the examination table. The right arm is fully extended and placed behind the head to expand the intercostal spaces (the spaces between the ribs), providing optimal access to the liver.

The certified technician or radiologist applies a water-based coupling gel to the skin over the right lower rib cage. The specialized Fibroscan probe is then placed perpendicular to the skin surface in an intercostal space overlying the right lobe of the liver. The operator activates the probe, which sends a mild, low-frequency vibration (shear wave) through the skin into the liver. The patient will feel a slight, painless flick or thumping sensation against the skin with each measurement; this is completely normal and does not cause discomfort.

The equipment’s software automatically records the velocity of the shear wave as it travels through the liver tissue, converting it into a liver stiffness measurement (LSM) expressed in kilopascals (kPa). Simultaneously, the Controlled Attenuation Parameter (CAP) is measured in decibels per meter (dB/m) to quantify the degree of hepatic steatosis (fatty change). The operator takes at least 10 valid measurements to ensure statistical reliability. Once the required measurements are obtained, the gel is wiped off, and the patient can immediately resume normal daily activities, including driving and eating.

When is an Ultrasound Fibroscan Performed?

Chronic Viral Hepatitis Management

Physicians frequently request an Ultrasound Fibroscan for patients diagnosed with chronic Hepatitis B or Hepatitis C. Chronic viral infections cause persistent inflammation of the hepatocytes, leading to progressive collagen deposition and fibrogenesis. A Fibroscan is performed to stage the baseline level of liver fibrosis (from F0 to F4) before starting antiviral therapy. It is also used periodically to monitor the regression of fibrosis or to detect early signs of cirrhosis, helping clinicians determine the duration and efficacy of antiviral regimens.

Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

With the rising prevalence of obesity, type 2 diabetes, and metabolic syndrome, MASLD (formerly NAFLD) has become a leading cause of chronic liver disease worldwide. Physicians order a Fibroscan to differentiate between simple hepatic steatosis (fat accumulation without significant inflammation) and metabolic dysfunction-associated steatohepatitis (MASH), which involves active inflammation and progressive scarring. The test provides both the CAP score to quantify fat and the LSM score to assess underlying fibrosis, guiding lifestyle and pharmacological interventions.

Alcoholic Liver Disease Assessment

Chronic, excessive alcohol consumption leads to a spectrum of liver injuries, including fatty liver, alcoholic hepatitis, and eventually cirrhosis. An Ultrasound Fibroscan is utilized to evaluate the severity of liver damage in patients with a history of alcohol abuse. By quantifying liver stiffness, the test helps clinicians identify patients at high risk of developing portal hypertension and liver failure, reinforcing the clinical necessity of alcohol cessation and guiding supportive medical therapies.

Autoimmune and Cholestatic Liver Diseases

Conditions such as Autoimmune Hepatitis (AIH), Primary Biliary Cholangitis (PBC), and Primary Sclerosing Cholangitis (PSC) involve immune-mediated destruction of liver cells or bile ducts. These chronic inflammatory processes inevitably lead to progressive liver fibrosis. A Fibroscan is performed to monitor these patients non-invasively over time, reducing the need for repeated, painful liver biopsies and helping specialists adjust immunosuppressive or cholestatic therapies based on objective tissue elasticity trends.

Investigation of Unexplained Abnormal Liver Function Tests

When routine blood tests reveal persistently elevated liver enzymes (such as Alanine Aminotransferase [ALT] and Aspartate Aminotransferase [AST]) without an obvious cause, an Ultrasound Fibroscan is indicated. It serves as a highly sensitive screening tool to detect occult liver disease, silent fibrosis, or significant fatty infiltration that may not be apparent on standard abdominal ultrasounds, allowing for early diagnosis and targeted clinical workups.

What Does an Ultrasound Fibroscan Detect?

An Ultrasound Fibroscan is exceptionally sensitive in detecting and quantifying a wide range of hepatic parenchymal alterations. The primary clinical findings detected by this diagnostic modality include:

• Absence of Fibrosis (F0): Indicates healthy, highly elastic liver tissue with no detectable scarring.
• Mild Fibrosis (F1): Detects early, localized scarring confined to the portal tracts of the liver.
• Moderate Fibrosis (F2): Identifies periportal fibrosis with few septae extending into adjacent liver lobules.
• Severe Fibrosis (F3): Detects bridging fibrosis, where extensive scarring connects different portal and central areas of the liver, significantly altering tissue architecture.
• Cirrhosis (F4): Identifies advanced, irreversible scarring characterized by nodular regeneration and severe tissue stiffness, placing the patient at risk for portal hypertension.
• Absence of Steatosis (S0): Indicates normal liver fat content (affecting less than 11% of hepatocytes).
• Mild Hepatic Steatosis (S1): Detects mild fatty infiltration, with fat droplets present in 11% to 33% of hepatocytes.
• Moderate Hepatic Steatosis (S2): Identifies moderate fatty liver changes, with fat accumulation involving 34% to 66% of hepatocytes.
• Severe Hepatic Steatosis (S3): Detects severe fatty infiltration, affecting more than 67% of the liver cells.
• Treatment Response: Monitors the reduction in liver stiffness following successful antiviral or lifestyle interventions.
• Disease Progression: Tracks the gradual increase in liver stiffness over time in patients with unmanaged chronic liver conditions.
• Early Portal Hypertension Risk: Correlates high liver stiffness values with an increased risk of developing esophageal varices and splenomegaly.
• Post-Transplant Liver Monitoring: Evaluates the health of a transplanted liver graft to detect early recurrence of hepatitis or graft fibrosis.
• Drug-Induced Liver Injury (DILI): Assesses the impact of hepatotoxic medications on liver tissue stiffness and structure.
• Cardiac Cirrhosis: Detects passive hepatic congestion and secondary stiffness caused by chronic right-sided heart failure.
• Hemochromatosis-Related Fibrosis: Evaluates liver scarring resulting from chronic iron overload.
• Wilson’s Disease Involvement: Assesses hepatic damage and fibrosis caused by abnormal copper accumulation.
• Biliary Obstruction Effects: Detects secondary increases in liver stiffness due to prolonged biliary tract obstruction.
• Fatty Liver Resolution: Documents the clearance of hepatic fat following significant weight loss or metabolic control.
• Inconclusive Results due to Ascites: Identifies cases where excessive free abdominal fluid prevents the accurate transmission of shear waves.

Turnaround Time and Report Access at Chughtai Lab

Chughtai Lab is widely recognized for its efficiency, clinical accuracy, and patient-centric services across Pakistan. The reporting process for an Ultrasound Fibroscan is designed to be seamless and rapid. Once the examination is completed, the raw quantitative data (LSM and CAP scores) are analyzed by a qualified consultant radiologist or hepatologist who specializes in liver elastography.

The finalized, medically verified report is typically available within a few hours of the procedure, and almost always on the same day. Chughtai Lab offers multiple convenient methods for patients to access their diagnostic reports. Patients can download their electronic reports in PDF format directly from the official Chughtai Lab website or through the dedicated Chughtai Lab Mobile App. Additionally, reports can be sent directly to the patient’s registered WhatsApp number, eliminating the need for a second visit to the diagnostic center. Physical copies of the report, complete with high-resolution graphical representations of the elastography measurements, can also be collected from the reception desk of the respective Chughtai Lab branch.

Ultrasound Fibroscan Findings Overview

The following table outlines the key parameters evaluated during an Ultrasound Fibroscan, comparing normal reference ranges with potential abnormal findings and their clinical implications:

Parameter Evaluated	Normal Findings	Possible Abnormal Findings
Liver Stiffness Measurement (LSM)	2.0 to 7.0 kPa (Indicates normal liver elasticity, corresponding to F0-F1 staging).	> 7.0 kPa to > 12.5 kPa (Indicates progressive fibrosis, with values above 12.5-14.0 kPa strongly suggestive of F4 Cirrhosis).
Controlled Attenuation Parameter (CAP)	< 238 dB/m (Indicates normal hepatic fat content, corresponding to S0).	≥ 238 dB/m to ≥ 280 dB/m (Indicates mild to severe hepatic steatosis, corresponding to S1-S3 fatty liver).
Interquartile Range / Median Ratio (IQR/med)	≤ 30% (Indicates high measurement reliability and low variability among the 10 valid acquisitions).	> 30% (Indicates high variability, reducing the clinical reliability of the test; may require a repeat scan).
Success Rate	≥ 60% (Indicates a highly successful and reliable acquisition process).	< 60% (Indicates poor acoustic window or technical difficulty, often due to severe obesity or ascites).
Hepatic Parenchymal Compliance	High compliance and elasticity; normal propagation of shear waves.	Reduced compliance; rapid shear wave propagation indicating dense collagen deposition.
Steatosis Grade Correlation	S0 (No significant fat accumulation detected in hepatocytes).	S1, S2, or S3 (Mild, moderate, or severe fatty infiltration of the liver parenchyma).
Fibrosis Stage Correlation	F0 – F1 (No fibrosis or minimal portal fibrosis).	F2, F3, or F4 (Moderate, severe, or advanced cirrhotic remodeling of liver tissue).

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient’s symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Chughtai Lab for Ultrasound Fibroscan?

• Experienced Healthcare Professionals: Your Fibroscan is performed and interpreted by highly trained radiologists and clinical technicians specializing in advanced liver elastography.
• Patient-Focused Care: Chughtai Lab prioritizes patient comfort, ensuring a gentle, painless, and stress-free diagnostic experience.
• Quality Diagnostic Services: Adherence to strict international quality control standards guarantees highly reproducible and clinically accurate results.
• Professional Reporting: Comprehensive, easy-to-understand reports featuring detailed quantitative LSM and CAP scores, complete with graphical interpretations.
• Modern Diagnostic Approach: Utilization of advanced, genuine Fibroscan® technology, avoiding outdated or uncalibrated equipment.
• Comfortable Environment: State-of-the-art, hygienic, and welcoming diagnostic facilities designed to make your visit pleasant.
• Convenient Locations: A vast network of diagnostic centers across Lahore, Karachi, Islamabad, and other major cities in Pakistan, making advanced healthcare highly accessible.
• Commitment to Accurate Diagnosis: Seamless integration of your Fibroscan results with Chughtai Lab’s extensive pathology services, such as Liver Function Tests (LFTs) and viral load testing, for a comprehensive clinical assessment.